

Figure 1




Figure 2




Figure 3





Figure 4






Figure 5A




Figure 5B

Figure 6




Figure 7





Figure 8

	Total (N = 29)		Total (N = 29)
Median age, (range)	60 (50 – 75)	Type of myeloma, ^b n (%)	
Female, n (%)	15 (52)	IgG	15 (52)
Extramedullary plasmacytomas ≥1, n (%)	4 (14)	IgA	1 (3)
Bone marrow plasma cells ≥60%, n (%)	7 (24)	IgM	1 (3)
Median years since diagnosis (range)	6 (2 – 16)	IgD	1 (3)
High-risk cytogenetic profile, ^a n (%)	7 (25)	Biclonal	1 (3)
del17p	4 (14)	Light chain	10 (35)
t(14;16)	2 (7)	Prior autologous transplantation, n (%)	25 (86)
t(4;14)	1 (4)	Triple-exposed, ^c n (%)	29 (100)
Median prior lines of therapy, n (range)	5 (3 – 18)	Triple-refractory	25 (86)
Received bridging therapy, n (%)	24 (83)	Penta-exposed, ^d n (%)	21 (72)
		Penta-refractory	9 (31)


^aBy central FISH, ^bBy immunofixation, ^cPI, IMiD, and anti-CD38, ^d≥2 PIs, ≥2 IMiDs, and anti-CD38

Figure 9




^aGraded according to Lee *et al. Blood* 2014;124:188, ^bSame patient with DLT of prolonged grade 4 CRS. AE=adverse event; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CRS=cytokine release syndrome

Figure 10



^aSerum M-protein, urine M-protein, or difference between involved and uninvolved free light chain (dFLC). *Bence-Jones proteinuria at baseline, with a transient response during bridging therapy; output represents dFLC value

Figure 11



^aPR or better; Independent Review Committee-assessed, ^bNo patient had stable disease or progressive disease as best response.
CR=complete response; ORR=overall response rate; PR=partial response; sCR=stringent complete response; VGPR=very good partial response

Figure 12




Figure 13





Figure 14



- * CD3+ CAR+ cells and transgene levels showed expansion in both blood and bone marrow
- * Median time to peak of expansion (C_{max}) was ~13 days after infusion
- * At 90 days, ~40% of evaluable patients^a had detectable peripheral CAR transgene levels and CD3 CAR+ cells
- * Preferential CD8+ central memory phenotype observed at the peak of expansion

PK Parameter	Mean CAR Transgene Level (SD)
C_{max}	35,596 (17972)
$AUC_{(0-28d)}$	343,146 (195765)
C_{min} , units: copy/ μ g gDNA; AUC units: copy/ μ g gDNA x day (Ph1b, N = 29)	

^aPatients with >90 days of collected PK samples (n=25); LLOQ=lower limit of quantitation

Figure 15

Bone Marrow, n (%)	Sensitivity Threshold (NGS)		
	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶
Day 28			
MRD-evaluable ^a	15	12	8
MRD negative	15 (100)	12 (100)	7 (88)
Month 6			
MRD-evaluable	5	5	3
MRD negative	5 (100)	5 (100)	3 (100)
Month 12			
MRD-evaluable	1	1	1
MRD negative	1 (100)	1 (100)	1 (100)

^aEvaluable samples are those that have passed calibration and had sufficient cells for evaluation at the respective testing threshold.
MRD=minimal residual disease; NGS=next generation sequencing

Figure 16






Figure 17



- Across all patients, IL-6 levels peaked at Days 7–14 post-cilta-cel infusion, as did IL-10 and IFN-γ levels
- CRP and ferritin trends follow cytokine levels and can be useful in monitoring CRS
- No association was observed between CRS severity and baseline^a or peak levels of CRP or ferritin

^aData not shown.
BL, baseline; C_{max}, maximum concentration; CRP, C-reactive protein; CRS, cytokine release syndrome; IL, interleukin; IQR, interquartile range; SE, standard error.


Figure 18



CRS severity and supportive measures were associated with peak IL-6 levels, as well as peak levels of IL-10 and IFN- γ ^b

^aAdditional dose of tocilizumab, steroids, and/or anakinra; ^bData not shown
C_{max}, maximum concentration; CRS, cytokine release syndrome; IL, interleukin.

Figure 19



CRS severity was associated with peak IL-10 and IFN- γ levels

Results were similar for other cytokines including IL-2, IL-8, soluble IL-2Ra, and TNF α ^a

^aData not shown.
 C_{max} , maximum concentration; CRS, cytokine release syndrome; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.




Figure 20

Figure 21




Figure 22





Figure 23






Figure 24A




Figure 24B




Figure 24C




Figure 25A




Figure 25B




Figure 25C




Figure 26A




Figure 26B




Figure 26C




Figure 27A




Figure 27B




Figure 27C

Figure 28




Figure 29A




Figure 29B




Figure 30




Figure 31




Figure 32

